List of Excipients in Branded Drug DUPIXENT

Dupixent Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Dupixent (dupilumab) is a high-value biologic with a formulation built around a small, conventional excipient system: arginine hydrochloride, histidine, polysorbate 80, sodium acetate, sucrose, and water for injection. The commercial opportunity is concentrated in sterile, high-purity excipients, low-particle biologic manufacturing, prefilled delivery systems, and alternative formulations that improve injection tolerability, storage, or device performance. Dupixent’s excipient composition is publicly disclosed, but the product’s commercial protection primarily derives from biologic patents, manufacturing know-how, formulation claims, regulatory exclusivity, and device integration rather than from broad ownership of the individual excipients. [1]

What excipients are used in Dupixent?

Dupixent is a sterile subcutaneous solution of recombinant human monoclonal antibody dupilumab. The FDA labeling identifies the following inactive ingredients:

Excipient	Primary formulation role	Commercial relevance
L-arginine hydrochloride	Stabilizer and solubility aid	Supports high-concentration protein formulation and reduces aggregation risk
L-histidine	Buffer component	Controls pH during storage
Polysorbate 80	Surfactant	Limits protein adsorption and interface-induced aggregation
Sodium acetate	Buffer component and ionic-strength modifier	Supports pH control and solution robustness
Sucrose	Tonicity agent and stabilizer	Helps protect the antibody during storage and freezing or temperature excursions
Water for injection	Vehicle	Sterile parenteral carrier

The labeled Dupixent solution has an approximate pH of 5.9. The commercial presentations include 200 mg/1.14 mL and 300 mg/2 mL prefilled syringes and prefilled pens, with some markets also using single-dose vials. [1]

The excipient system is designed for a liquid monoclonal-antibody product administered subcutaneously. It does not rely on a complex lyophilized cake, a lipid nanoparticle, or a specialized depot technology.

Why does Dupixent use arginine, histidine, polysorbate 80, acetate, and sucrose?

The formulation uses complementary excipient functions rather than a single proprietary stabilizer.

Arginine hydrochloride

Arginine is commonly used in protein formulations to improve solubility and reduce self-association. At high antibody concentrations, proteins can experience reversible and irreversible aggregation, increased viscosity, and difficult syringeability. Arginine can reduce protein-protein interactions, although its effect depends on concentration, pH, protein surface chemistry, and ionic strength.

For Dupixent, arginine hydrochloride is commercially important because it can support a concentrated liquid product without requiring a large increase in surfactant or a switch to lyophilization.

Histidine and sodium acetate

Histidine is widely used as a biologic buffer because it provides useful buffering capacity in mildly acidic formulations and has a relatively limited interaction profile with proteins. Sodium acetate provides additional pH and ionic-strength control.

The combination gives the manufacturer flexibility during development and scale-up. Buffer systems affect aggregation, chemical degradation, viscosity, subvisible particle formation, and compatibility with container-closure materials.

Polysorbate 80

Polysorbate 80 protects the antibody from adsorption to glass, elastomeric components, syringe surfaces, and air-liquid interfaces. It is particularly important for products exposed to agitation, shipping vibration, and repeated interaction with delivery-device components.

Polysorbate 80 also creates a major control point. It can undergo oxidation and hydrolysis, generating degradants that may affect protein stability or contribute to particle formation. Suppliers must control peroxide levels, fatty-acid composition, hydrolysis products, and lot-to-lot variability.

Sucrose

Sucrose contributes to tonicity and protects the antibody structure. It can reduce conformational stress during temperature changes and manufacturing operations. As a nonreducing sugar, sucrose is generally preferred over reducing sugars for many protein formulations because it presents less risk of Maillard-type reactions with protein residues.

What formulation opportunities exist for Dupixent competitors?

The strongest opportunities are not simple substitutions of one listed excipient. A competitor would need to demonstrate equivalent or superior stability, manufacturability, injection performance, and regulatory comparability.

High-concentration formulations

Dupilumab is administered subcutaneously, so dose volume and injection force affect patient acceptance. A formulation that delivers the same dose in a smaller volume could improve:

• Injection time
• Autoinjector performance
• Needle gauge options
• Patient comfort
• Shipping and packaging efficiency
• Device usability for chronic dosing

The technical challenge is that increasing concentration can raise viscosity, aggregation risk, opalescence, and injection force. Arginine, histidine, surfactants, sugars, amino acids, and polyols can be screened to improve the concentration-performance balance.

Low-viscosity formulations

A lower-viscosity formulation could permit smaller needles or shorter injection times. The opportunity is commercially relevant for chronic atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other long-term Dupixent indications.

The formulation developer must preserve potency and purity while avoiding increases in protein-protein interaction. Excipient selection, pH, ionic strength, protein concentration, and temperature history must be optimized together.

Polysorbate alternatives

Polysorbate degradation is a recognized development and manufacturing issue for monoclonal antibodies. Alternatives include poloxamers and certain nonionic surfactants, although each has its own extractables, compatibility, stability, and regulatory profile.

A successful polysorbate-reduced or polysorbate-free formulation could create a differentiated patent position if it shows improved stability or lower particle formation. The regulatory burden remains significant because the change may affect critical quality attributes and container-closure compatibility.

Low-temperature and room-temperature stability

Dupixent is distributed as a refrigerated biologic, with handling requirements specified in the prescribing information. A formulation with longer room-temperature stability could reduce cold-chain costs, improve pharmacy logistics, and reduce product loss from temperature excursions.

Commercial value would depend on the actual shelf-life extension. A modest improvement may have limited impact for specialty pharmacy distribution, while a meaningful increase in allowable unrefrigerated time could support home delivery and patient self-administration.

Alternative delivery systems

The excipient strategy is closely linked to device design. Relevant opportunities include:

• Smaller-volume prefilled syringes
• Higher-capacity autoinjectors
• Wearable injectors
• Needle-free systems
• Dual-chamber devices for unstable liquid formulations
• Connected devices that record dose administration

Any device change can alter shear exposure, silicone-oil contact, extractables, injection force, and delivered volume. Formulation and device development must therefore proceed as an integrated program.

What patents protect Dupixent’s formulation and excipient strategy?

Dupixent’s individual excipients are established pharmaceutical materials and are generally available from multiple qualified suppliers. Commercial protection is more likely to arise from claims directed to:

1. Dupilumab itself and antibody sequences.
2. Specific therapeutic uses.
3. Pharmaceutical compositions containing dupilumab and defined excipient ranges.
4. Concentration, pH, stability, or storage conditions.
5. Subcutaneous administration regimens.
6. Prefilled syringes, autoinjectors, or container-closure systems.
7. Manufacturing and purification processes.
8. Combination treatment methods.

A formulation patent can be commercially meaningful if it claims a narrow but difficult-to-design-around combination of protein concentration, pH, buffer, stabilizer, surfactant, and storage conditions. It is weaker if it covers only conventional excipients at broad, predictable ranges without evidence of an unexpected stability or usability benefit.

The public disclosure of Dupixent’s excipients does not eliminate potential patent protection. A patent may still protect a specific concentration range, ratio, pH window, delivery format, or performance result. It does, however, make a simple substitution strategy easier for competitors to evaluate.

When does Dupixent lose exclusivity, and how do excipients affect generic entry?

Dupixent is a biologic, so the relevant competitors are biosimilars or interchangeable biosimilars rather than conventional small-molecule generics. FDA approval follows the Biologics Price Competition and Innovation Act pathway under section 351(k) of the Public Health Service Act. [2]

The excipient system affects biosimilar development in three ways.

First, a biosimilar may use the same excipients to reduce formulation risk and support analytical comparability. Second, a biosimilar may use a different excipient system if it can demonstrate comparable safety, purity, potency, and clinical performance. Third, a formulation change can create device and administration differences that require additional justification.

Unlike a small-molecule ANDA, a biosimilar applicant cannot rely only on sameness of inactive ingredients. The product must be highly similar to the reference biologic, and differences must not affect safety or efficacy. FDA’s biosimilar guidance allows formulation differences in some circumstances, but the applicant must address their impact through analytical and clinical evidence. [3]

The commercial launch date depends on the combined effect of:

• Twelve-year reference-product exclusivity under the U.S. biologics framework.
• Patent expiration and patent litigation.
• Patent settlements and license agreements.
• Regulatory review timing.
• Manufacturing readiness.
• Interchangeability strategy.
• Device and presentation approvals.

A biosimilar using a different excipient system may gain differentiation, but it may also increase comparability and clinical-development complexity.

What is the FDA regulatory status of Dupixent formulations?

The FDA approved Dupixent in March 2017 for moderate-to-severe atopic dermatitis in adults whose disease was not adequately controlled with topical prescription therapies or when those treatments were not advisable. The label has since expanded to include additional age groups and indications, including asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease in specified populations. [1,4]

The principal commercial presentations are:

• Single-dose prefilled syringe
• Single-dose prefilled pen
• Single-dose vial in certain presentations and markets

For a follow-on product, the formulation and device must be evaluated together. A biosimilar approved in a vial may not immediately compete with a pen presentation on equal commercial terms. Patient training, payer requirements, specialty-pharmacy handling, and prescriber preference can influence substitution.

Which companies have commercial opportunities in Dupixent excipients?

The most direct opportunity is upstream supply of high-quality excipients rather than ownership of the Dupixent formulation.

Excipient manufacturers

Potential suppliers can compete on:

• Low-peroxide polysorbate 80
• High-purity arginine hydrochloride
• Low-endotoxin histidine and acetate buffers
• Pharmaceutical-grade sucrose
• Consistent particle and bioburden profiles
• Global regulatory documentation
• Dual sourcing and supply continuity

Polysorbate 80 has the strongest technical differentiation because oxidation and hydrolysis can affect biologic stability. Suppliers offering tighter impurity controls, improved analytical packages, and reliable global supply can capture value even when the excipient itself is not patent-protected.

Contract development and manufacturing organizations

CDMOs can offer value through:

• High-concentration antibody formulation screening
• Subvisible-particle analytics
• Container-closure compatibility
• Prefilled-syringe filling
• Autoinjector assembly
• Stability studies
• Biosimilar comparability packages

The most defensible CDMO position combines formulation expertise with sterile fill-finish and device integration.

Device manufacturers

A smaller-volume or higher-concentration Dupixent competitor could create demand for new autoinjectors, wearable injectors, or low-force syringes. Device suppliers with validated systems for viscous biologics have a stronger position than suppliers selling generic delivery hardware.

How strong is the excipient-based patent opportunity?

The patent opportunity is moderate for genuinely differentiated formulations and weak for ordinary substitution.

Strategy	Technical value	Patent potential	Commercial risk
Same excipients at different concentrations	Medium	Low to medium	Design-around and obviousness risk
Polysorbate-reduced formulation	Medium to high	Medium	Stability and comparability risk
Higher-concentration formulation	High	Medium to high	Viscosity and injection-force risk
Room-temperature-stable formulation	High	High	Long development and shelf-life evidence
New device with existing formulation	High	Medium to high	Device clearance and manufacturing risk
Lyophilized formulation	Medium	Medium	Reconstitution burden and patient usability
Novel excipient system	Potentially high	High	Regulatory and safety uncertainty

The strongest formulation programs generate data showing a measurable benefit, such as lower aggregation, reduced particles, lower injection force, longer stability, or improved device performance. Patent claims supported only by routine excipient optimization face greater validity and freedom-to-operate pressure.

What is the revenue exposure for Dupixent formulation suppliers?

Dupixent is one of the largest biologic products in the immunology and inflammatory-disease markets. Sanofi reported 2024 Dupixent net sales of approximately €13.1 billion. [5] That scale creates meaningful demand for:

• Pharmaceutical-grade excipients
• Sterile filling
• Syringes and pens
• Autoinjector components
• Cold-chain packaging
• Analytical testing
• Biosimilar development services

Excipient cost is a small portion of the product’s selling price. The larger opportunity lies in reducing manufacturing losses, extending shelf life, improving device throughput, enabling smaller injection volumes, or supporting follow-on products. A supplier that improves biologic stability can capture value disproportionate to the unit price of the excipient.

What generic launch scenarios exist for Dupixent?

A conventional generic launch is not the relevant scenario. The principal scenarios are:

1. A biosimilar launches after regulatory exclusivity and patent barriers are resolved.
2. A biosimilar launches in a vial presentation before matching the pen.
3. A biosimilar uses the same excipients to reduce comparability risk.
4. A biosimilar uses a differentiated formulation to improve injection volume or storage.
5. A settlement permits entry on a negotiated date.
6. A device or formulation patent delays one presentation but not another.

The most commercially credible entrant will likely prioritize analytical similarity, reliable sterile manufacturing, a familiar delivery device, and payer access. Excipient differentiation alone is unlikely to displace Dupixent.

Key Takeaways

• Dupixent uses arginine hydrochloride, histidine, polysorbate 80, sodium acetate, sucrose, and water for injection.
• The formulation is a conventional liquid monoclonal-antibody system optimized for subcutaneous delivery.
• Polysorbate 80 quality and degradation control are important technical and supply-chain issues.
• The strongest commercial opportunities involve high-concentration formulations, lower injection force, improved room-temperature stability, and integrated devices.
• Dupixent competitors are biosimilars, not conventional generics.
• Excipient patents are most valuable when linked to measurable stability, delivery, or manufacturing improvements.
• Dupixent’s multibillion-euro annual sales support opportunities in excipient supply, CDMO services, sterile filling, device technology, and biosimilar development.

FAQs

Can a biosimilar use different excipients from Dupixent?

Yes. A biosimilar may use different excipients if the product remains highly similar and the differences do not affect safety, purity, potency, or clinical performance.

Is polysorbate 80 the main formulation risk in Dupixent?

It is one of the main technical control points because oxidation and hydrolysis can generate degradants and contribute to protein particle formation. The risk depends on supplier quality, processing, packaging, and storage.

Can a new excipient create freedom to operate around Dupixent?

Potentially, but a new excipient does not by itself avoid antibody, method-of-use, manufacturing, device, or concentration patents. Freedom to operate requires review of the complete patent estate.

Would a higher-concentration Dupixent formulation have immediate commercial value?

Yes, if it reduces injection volume or improves device performance without increasing aggregation, viscosity, injection force, or immunogenicity risk.

Are Dupixent excipients protected as a proprietary combination?

The individual excipients are established pharmaceutical materials. Protection, where available, is more likely to cover defined formulation ranges, stability characteristics, delivery systems, manufacturing processes, or therapeutic uses than the generic names of the excipients alone.

References

1. U.S. Food and Drug Administration. (2024). Dupixent (dupilumab) prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Biological product patent information and reference product exclusivity under the Public Health Service Act. https://www.fda.gov
3. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. https://www.fda.gov
4. U.S. Food and Drug Administration. (2024). Dupilumab approval history and supplemental indications. https://www.fda.gov
5. Sanofi. (2025). 2024 annual report and fourth-quarter financial results. https://www.sanofi.com